Targeting severe acute respiratory syndrome-coronavirus (SARS-CoV-1) with structurally diverse inhibitors: a comprehensive review

Hosseini‐Zare, Maryam Sadat; Thilagavathi, Ramasamy; Selvam, Chelliah

doi:10.1039/d0ra04395h

Cited by 15 publications

(16 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HIS:41 and CYS:145 have been known as essential residues during MPro enzymatic activity (Tahir ul Qamar et al, 2020). Inhibiting these residues has a promising effect on preventing virus replication and prevent viral spreading throughout the tissues (Ahkam et al, 2020;Gyebi et al, 2020;Hosseini-Zare et al, 2020;Tahir ul Qamar et al, 2020).…”

Section: Resultsmentioning

confidence: 99%

Exploring public health benefits of Dolichos lablab as a dietary supplement during the COVID-19 outbreak: A computational study

Purwanti¹,

Hermanto²,

Wiliem³

et al. 2020

J Appl Pharm Sci

View full text Add to dashboard Cite

The emerging case of coronavirus disease-19 (COVID-19) caused by the severe acute respiratory syndromecoronavirus (SARS-CoV-2) virus has become a global health issue. Since there is no available developed vaccine, health-promoting foods play a vital role in maintaining the immune system against the disease. Dolichos lablab (DL), an unutilized highly nutritional legume, has an excellent potential to cope with this pandemic with various health benefit phytochemicals. This study appraised the possibility of phytochemical content from DL to prevent virus infection and hyperinflammation in COVID-19 in silico. DL's phytochemicals from liquid chromatography-high-resolution mass spectrometry analysis were docked with several SARS-CoV-2 proteins, including main protease and HR. Also, NF-κB docking was executed to pursue anti-inflammatory properties. The drug-likeness properties of screened phytochemicals were then evaluated using SwissADME. According to the results, there were 16 phytochemicals with a high affinity to targeted proteins. Among those, five phytochemicals consistently gave a low binding affinity to all targeted proteins. Those five phytochemicals' physicochemical properties, except for rutin and (9cis)-retinal, also coped with small-molecule bioavailability, permeability, and flexibility according to the SwissADME calculations. In conclusion, DL has a high probability of complementing the medical effort as dietary supplementation to modulate the immune system and prevent viral infection.

show abstract

Section: Resultsmentioning

confidence: 99%

Exploring public health benefits of Dolichos lablab as a dietary supplement during the COVID-19 outbreak: A computational study

Purwanti¹,

Hermanto²,

Wiliem³

et al. 2020

J Appl Pharm Sci

View full text Add to dashboard Cite

show abstract

“…Replication of SARS-CoV-2 depends on PLpro and Mpro functions. Inhibitors of SARS-CoV PLpro, in several studies, have been shown to be as effective against SARS-CoV-2 PLpro [44, 45]. Although many of the findings were promising, the development in introducing effective drugs is lagging.…”

Section: Discussionmentioning

confidence: 99%

Losartan promotes cell survival following SARS-CoV-2 infectionin vitro

Nejat

Sadr

Freitas

et al. 2020

Preprint

View full text Add to dashboard Cite

IntroductionCoronavirus disease 2019 (COVID-19) can be associated with mortality and high morbidity worldwide. There is an extensive effort to control infection and disease caused by SARS-CoV-2. This study addressed the hypothesis that angiotensin II type I receptor blocker, Losartan, may restrict pathogenesis caused by SARS-CoV-2 by decreasing viral-induced cytopathological changes by blocking angiotensin II type 1 receptor (AT1R), thus reducing the affinity of the virus for ACE2, and inhibiting papain-like protease of the virus.MethodLosartan inhibitory effect on deubiquitination and deISGylation properties of papain-like protease was investigated using a fluorescence method and gel shift analysis determining its inhibitory effects.The inhibitory effect of Losartan on SARS-CoV-2 cell replication was investigated both when losartan was added to the cell culture 1 hour before (pre-infection group) and 1 hour after (post-infection group) SARS-CoV-2 infection of Vero E6 cells.ResultsLosartan treatment of Vero E6 cells prior to and after SARS-CoV-2 infection reduced SARS-CoV-2 replication by 80% and 70% respectively. Losartan was not a strong deubiquitinase and deISGylase inhibitor of PLpro.ConclusionLosartan added pre- and post-infection to the Vero E6 cell culture significantly prevents cell destruction and replication by SARS-CoV2. Losartan has low side-effects, is readily available, and can be produced at high levels globally, all features of a promising drug in treatment of COVID-19 if validated by clinical trials.

show abstract

“…Substrates of 3CLpro are peptides, and therefore peptidic inhibitors derived from the substrates have been developed against 3CLpro [67] . To enhance the binding affinity of peptidic inhibitors to 3CLpro, amino acids of the substrate were substituted to fit the binding pocket perfectly.…”

Section: Inhibiting the Viral Genome Replicationmentioning

confidence: 99%

Drug discovery and development targeting the life cycle of SARS-CoV-2

Xu¹,

Jiang²

2021

Fundamental Research

View full text Add to dashboard Cite

Targeting severe acute respiratory syndrome-coronavirus (SARS-CoV-1) with structurally diverse inhibitors: a comprehensive review

Abstract: Since the coronaviruses that cause COVID-19 and SARS-CoV-1 share 80% structural similarity, we present a comprehensive review of the diverse molecular inhibitors of SARS-CoV-1. This will help to accelerate drug discovery for deadly coronavirus diseases.

Cited by 15 publications

References 115 publications

Exploring public health benefits of Dolichos lablab as a dietary supplement during the COVID-19 outbreak: A computational study

Exploring public health benefits of Dolichos lablab as a dietary supplement during the COVID-19 outbreak: A computational study

Losartan promotes cell survival following SARS-CoV-2 infectionin vitro

Drug discovery and development targeting the life cycle of SARS-CoV-2

Contact Info

Product

Resources

About